Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Jan 3, 2024

SOMERSET, N.J.--(BUSINESS WIRE)--Jan. 3, 2024-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).1 Under the terms of the license agreement, Legend Biotech will receive a $100 million upfront cash payment.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at https://legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.


1 ClinicalTrials.gov. DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05680922. Last accessed Nov 2023.

Press contact:
Alexandra Ventura, Corporate Communications & Investor Relations, Legend Biotech

Investor contact:
Jessie Yeung, Head of Investor Relations & Public Relations, Legend Biotech

Source: Legend Biotech Corporation


You are about to leave Investors.LegendBiotech.com